Parosteal Osteosarcoma

Parosteal osteosarcoma is a low-grade osteosarcoma arising from the outer fibrous layer of the periosteum, growing outward onto the cortical surface rather than from the medullary cavity. It is the commonest of the surface osteosarcomas and accounts for roughly 4 to 6 per cent of all osteosarcomas.

Demographics

• Peak incidence in the third and fourth decades — a decade or two older than conventional intramedullary osteosarcoma, which peaks in adolescence.
• Slight female predominance in most published series.
• Reported from the second to the seventh decade; a paediatric case should prompt careful review of grade.

Anatomical distribution

Molecular biology

• Supernumerary ring chromosomes derived from 12q13-15, carrying amplification of MDM2 and CDK4.
• The same amplicon underlies low-grade central osteosarcoma and well-differentiated/dedifferentiated liposarcoma — a shared low-grade osteosarcoma family.
• Detected by FISH for MDM2 amplification or by immunohistochemistry for MDM2 and CDK4 nuclear expression. Reactive lesions (myositis ossificans, fracture callus) and osteochondroma are negative.
• Practical value: it resolves the bland-histology dilemma and it identifies the low-grade lineage of a dedifferentiated tumour whose high-grade component looks like any conventional osteosarcoma.

View larger

View larger

View larger

Biopsy principles

• Perform after complete staging imaging, never before — the biopsy tract distorts MRI and the tract must be planned to lie within the eventual resection field.
• Biopsy in, or under the direct governance of, the unit that will perform the definitive resection.
• Target the non-mineralised, enhancing component identified on MRI. A core through the dense ossified centre yields bland tissue and risks a false reassurance of low grade.
• Image-guided core needle biopsy is standard; a trephine may be needed for the ossified portion. Open biopsy through a longitudinal incision in line with the definitive approach if cores are non-diagnostic.
• Send fresh tissue for cytogenetics/FISH if the diagnosis is uncertain.

Macroscopic

Hard, lobulated, greyish-white mass with a broad cortical base; cut surface shows dense bone with fibrous septa. Any soft, fleshy, tan or haemorrhagic area is suspicious for dedifferentiation and must be sampled separately and labelled.

Microscopic

• Well-formed, parallel, often anastomosing woven bone trabeculae in a hypocellular bland spindle cell fibrous stroma.
• Trabeculae may show osteoblastic rimming and, unhelpfully, may mimic normal bone or fibrous dysplasia — the "streamer" or "picket-fence" pattern of parallel trabeculae is characteristic.
• Minimal cytological atypia, rare mitoses — hence grade 1 (occasionally grade 2 with increased cellularity and atypia).
• A cartilaginous cap is present in a minority and does not equal osteochondroma; the cap is disorganised and lacks the underlying medullary continuity.
• Dedifferentiated areas: an abrupt transition to a high-grade sarcoma — conventional high-grade osteosarcoma, fibrosarcoma-like, or undifferentiated pleomorphic sarcoma-like, with marked pleomorphism and mitotic activity.

Ancillary tests

• MDM2 amplification by FISH — the most reliable discriminator; positive in the large majority of parosteal osteosarcomas and negative in myositis ossificans, osteochondroma and fibrous dysplasia.
• MDM2 and CDK4 immunohistochemistry — nuclear positivity in both is highly supportive; sensitivity is lower than FISH, so a negative immunostain does not exclude the diagnosis.
• Amplification is retained in the dedifferentiated component, confirming clonal relationship.

• Enneking (MSTS) staging for surgical decision-making: low grade = stage I; intracompartmental IA, extracompartmental IB. Most parosteal osteosarcomas are stage IB because a surface tumour with a soft-tissue mass is by definition extracompartmental. Dedifferentiated disease is stage II.
• AJCC staging incorporates size, grade and metastasis; low-grade non-metastatic disease sits in stage I.
• Grading: grade 1 in the majority, grade 2 in a minority; a grade 3 focus defines dedifferentiation.
• Staging work-up: local MRI whole bone, CT of the primary, CT chest, and consideration of whole-body imaging if the grade is uncertain.

Decision framework

Chemotherapy has no established role in pure low-grade parosteal osteosarcoma. Radiotherapy has no routine role; it is reserved for unresectable or positive-margin disease where re-resection is impossible, and is of limited efficacy.

Wide en-bloc resection — PIPADRAW (posterior distal femoral lesion)

• Occurs in roughly 15 to 25 per cent of cases — but be clear which denominator you are quoting, because the two commonly cited figures count different things. Synchronous dedifferentiation, present in the resection specimen at diagnosis, was 7 of 79 (9 per cent) in the original Mayo series. The higher 15 to 25 per cent range counts tumours that harbour or later develop a high-grade component, so it includes metachronous dedifferentiation emerging in a recurrence, classically after inadequate primary excision. An examiner asking "what proportion dedifferentiate?" is usually asking the second question; an examiner asking "what will the pathologist find?" is asking the first.
• Defined by a discrete high-grade sarcomatous component juxtaposed against the low-grade parosteal tumour; the transition is typically abrupt.
• Retains MDM2 amplification, confirming clonal origin from the low-grade lesion.
• Clinical flags: new or increasing pain, accelerated growth in a long-standing mass, recurrence after prior surgery.
• Radiological flags: unmineralised enhancing soft-tissue nodule, cortical destruction, aggressive periosteal reaction, marrow oedema disproportionate to the ossified mass.
• Prognosis falls substantially, approaching that of conventional high-grade osteosarcoma, with metastatic risk concentrated in the lungs.
• Management: neoadjuvant and adjuvant chemotherapy on a conventional high-grade osteosarcoma protocol plus wide resection.

Oncological outcome

Surveillance. Local site imaging (radiograph, with MRI or CT as indicated by reconstruction) and CT chest at intervals of about 3 to 6 months for the first 2 to 3 years, then 6 to 12 monthly. Because recurrence 10 to 20 years after surgery is documented, follow-up should extend well beyond the 5-year point conventional for high-grade sarcoma, and patients must be told to report any new mass or pain at any time.

Complications

Global epidemiology. Osteosarcoma incidence is broadly similar worldwide at approximately 3 per million per year, with parosteal variants a consistent 4 to 6 per cent of that total across North American, European, Asian and Latin American series. Presentation stage, however, is not uniform: in settings with limited access to cross-sectional imaging and specialist pathology, parosteal osteosarcoma is more often excised as a presumed exostosis and presents to the sarcoma service as a recurrence.

Society guidance — where it genuinely addresses this topic

Registries. There is no implant registry directly relevant here, but national bone tumour registries (Rizzoli, Mayo, the Scandinavian Sarcoma Group registry, the Cooperative Osteosarcoma Study Group database) supply the outcome data that underpin the surgery-alone approach. National joint registries do contribute indirectly: AOANJRR, NJR and AJRR report the survivorship of tumour endoprostheses used for reconstruction, informing the counselling of a young adult about revision risk over decades.

Practice variation by resource setting

• High-resource settings: routine MRI whole bone, MDM2 FISH, navigation or patient-specific guides for hemicortical resection, vascularised fibula reconstruction.
• Middle-resource settings: MRI usually available but molecular testing may require referral; hemicortical resection performed on conventional planning; allograft supply may be limited, favouring endoprosthesis or bone transport.
• Limited-resource settings: radiograph and CT-led diagnosis; molecular confirmation unavailable; the priority is avoiding unplanned excision and achieving an oncologically clean operation, in which a well-executed amputation or a segmental resection with a simple reconstruction serves the patient better than an ambitious limb salvage without margin control.

Related pages. The lesions it is mistaken for, in order of how often: Myositis Ossificans - the zonation runs the opposite way; Osteochondroma - corticomedullary continuity settles it; and Fibrous Dysplasia, which the MDM2 stain separates. The rest of the family: Periosteal Osteosarcoma - intermediate grade, chondroblastic, diaphyseal, a different tumour despite the neighbouring name - and Osteosarcoma for the conventional high-grade disease a dedifferentiated tumour becomes. The same dedifferentiation logic in cartilage: Dedifferentiated Chondrosarcoma and Chondrosarcoma. Getting the operation right: Biopsy Principles and Techniques - because the unplanned excision is the commonest disaster here - plus Limb Salvage Surgery Principles and Allograft-Prosthetic Composite Reconstruction for the reconstruction whose ten-year survival is well below the patient's.